Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma
| Status: | Terminated |
|---|---|
| Conditions: | Cancer, Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | April 2008 |
| End Date: | September 2012 |
Strategies to Isolate and Expand Myeloma Specific T-cells Using Autologous B Cells as Antigen Presenting Cell B-APC
RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the
laboratory may help doctors learn more about T cells and plan better treatment for multiple
myeloma.
PURPOSE: This research study is looking at T cells in blood and bone marrow samples from
patients with multiple myeloma.
laboratory may help doctors learn more about T cells and plan better treatment for multiple
myeloma.
PURPOSE: This research study is looking at T cells in blood and bone marrow samples from
patients with multiple myeloma.
OBJECTIVES:
Primary
- To evaluate the feasibility of expanding myeloma-specific T cells using autologous ex
vivo expanded B cells loaded with myeloma antigens as antigen-presenting cells (B-APCs)
in peripheral blood and bone marrow samples from patients with multiple myeloma.
Secondary
- To examine the feasibility of selecting and expanding myeloma-specific T cells ex vivo
using interferon γ release and CD3/CD28 stimulation.
OUTLINE: Peripheral blood and bone marrow samples are collected periodically for laboratory
studies. Samples are analyzed to assess the feasibility of expanding autologous B cells ex
vivo using CD40L and IL-4; the antigen-presenting phenotype of autologous B-cell
antigen-presenting cells (B-APCs) using flow cytometry; and the antigen-presenting function
of B-APCs using ELISPOT and chromium-release assay. Myeloma-specific interferon γ secreting
T cells are isolated and selected using Miltenyi beads. The selected myeloma-specific T
cells are expanded ex vivo using anti CD3/CD28 beads.
Primary
- To evaluate the feasibility of expanding myeloma-specific T cells using autologous ex
vivo expanded B cells loaded with myeloma antigens as antigen-presenting cells (B-APCs)
in peripheral blood and bone marrow samples from patients with multiple myeloma.
Secondary
- To examine the feasibility of selecting and expanding myeloma-specific T cells ex vivo
using interferon γ release and CD3/CD28 stimulation.
OUTLINE: Peripheral blood and bone marrow samples are collected periodically for laboratory
studies. Samples are analyzed to assess the feasibility of expanding autologous B cells ex
vivo using CD40L and IL-4; the antigen-presenting phenotype of autologous B-cell
antigen-presenting cells (B-APCs) using flow cytometry; and the antigen-presenting function
of B-APCs using ELISPOT and chromium-release assay. Myeloma-specific interferon γ secreting
T cells are isolated and selected using Miltenyi beads. The selected myeloma-specific T
cells are expanded ex vivo using anti CD3/CD28 beads.
DISEASE CHARACTERISTICS:
- Diagnosis of multiple myeloma
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
We found this trial at
1
site
Barbara Ann Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
Click here to add this to my saved trials
